Ronald Kong

941 total citations
34 papers, 172 citations indexed

About

Ronald Kong is a scholar working on Molecular Biology, Pediatrics, Perinatology and Child Health and Clinical Biochemistry. According to data from OpenAlex, Ronald Kong has authored 34 papers receiving a total of 172 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Molecular Biology, 7 papers in Pediatrics, Perinatology and Child Health and 7 papers in Clinical Biochemistry. Recurrent topics in Ronald Kong's work include Metabolism and Genetic Disorders (7 papers), Biochemical and Molecular Research (6 papers) and Muscle Physiology and Disorders (5 papers). Ronald Kong is often cited by papers focused on Metabolism and Genetic Disorders (7 papers), Biochemical and Molecular Research (6 papers) and Muscle Physiology and Disorders (5 papers). Ronald Kong collaborates with scholars based in United States, Netherlands and Canada. Ronald Kong's co-authors include Diksha Kaushik, Lan Gao, Jiyuan Ma, Douglas A. Craig, Elizabeth Goodwin, Manuel Cajina, Joseph M. Colacino, John Babiak, Oscar L. Laskin and Neil G. Almstead and has published in prestigious journals such as Journal of Clinical Oncology, Journal of Medicinal Chemistry and European Journal of Pharmacology.

In The Last Decade

Ronald Kong

30 papers receiving 170 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ronald Kong United States 9 95 24 21 21 20 34 172
Dong Zhao United States 11 183 1.9× 21 0.9× 23 1.1× 42 2.0× 3 0.1× 15 408
Liliana Torres-López Mexico 8 102 1.1× 4 0.2× 19 0.9× 12 0.6× 4 0.2× 10 255
Laia Llovera Spain 7 135 1.4× 15 0.6× 3 0.1× 14 0.7× 9 0.5× 16 251
S Lenzen Germany 11 214 2.3× 6 0.3× 8 0.4× 53 2.5× 9 0.5× 16 408
Maurice Brollo France 4 80 0.8× 22 0.9× 9 0.4× 152 7.2× 27 1.4× 4 280
Lorraine Anderson United Kingdom 7 167 1.8× 4 0.2× 45 2.1× 46 2.2× 16 0.8× 8 374
Manfred Thomas United States 3 139 1.5× 16 0.7× 36 1.7× 26 1.2× 6 0.3× 6 191
Justyna M. Gawel Canada 5 181 1.9× 15 0.6× 10 0.5× 20 1.0× 25 1.3× 6 229
Yvonne Wohlfarter Austria 6 236 2.5× 61 2.5× 14 0.7× 82 3.9× 5 0.3× 8 327
Tetsushi Kataura Japan 8 111 1.2× 9 0.4× 11 0.5× 28 1.3× 8 0.4× 19 224

Countries citing papers authored by Ronald Kong

Since Specialization
Citations

This map shows the geographic impact of Ronald Kong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ronald Kong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ronald Kong more than expected).

Fields of papers citing papers by Ronald Kong

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ronald Kong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ronald Kong. The network helps show where Ronald Kong may publish in the future.

Co-authorship network of co-authors of Ronald Kong

This figure shows the co-authorship network connecting the top 25 collaborators of Ronald Kong. A scholar is included among the top collaborators of Ronald Kong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ronald Kong. Ronald Kong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gao, Lan, et al.. (2025). Endogenous tetrahydrobiopterin in humans: circadian rhythm, sex, race, age, and disease status. Frontiers in Pharmacology. 16. 1701617–1701617.
2.
3.
Flach, Stephen, et al.. (2024). Lack of Concentration‐QTc Relationship and Cardiac Risk With Vatiquinone Therapeutic and Supratherapeutic Doses. Clinical Pharmacology in Drug Development. 13(11). 1227–1238.
4.
Tine, Brian A. Van, Matthew Ingham, Steven Attia, et al.. (2024). Phase Ib Study of Unesbulin (PTC596) Plus Dacarbazine for the Treatment of Locally Recurrent, Unresectable or Metastatic, Relapsed or Refractory Leiomyosarcoma. Journal of Clinical Oncology. 42(20). 2404–2414. 3 indexed citations
5.
Thoolen, Martin, et al.. (2024). Effect of Itraconazole, a CYP3A4 Inhibitor, and Rifampin, a CYP3A4 Inducer, on the Pharmacokinetics of Vatiquinone. Clinical Pharmacology in Drug Development. 13(12). 1283–1290. 4 indexed citations
6.
Okudaira, Noriko, et al.. (2024). Determination of Vatiquinone Drug‐Drug Interactions, as CYP450 Perpetrator and Victim, Using Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation. The Journal of Clinical Pharmacology. 65(2). 160–169. 2 indexed citations
7.
Gao, Lan, Anuradha Bhattacharyya, Diksha Kaushik, et al.. (2024). Pharmacokinetics and pharmacodynamics of PTC518, an oral huntingtin lowering splicing modifier: A first‐in‐human study. British Journal of Clinical Pharmacology. 90(12). 3242–3251. 4 indexed citations
8.
9.
Gao, Lan, Diksha Kaushik, Brian A. Van Tine, et al.. (2023). Pharmacokinetics of dacarbazine and unesbulin and CYP1A2‐mediated drug interactions in patients with leiomyosarcoma. Clinical and Translational Science. 17(2). 1 indexed citations
10.
Laskin, Oscar L., Diksha Kaushik, Jiyuan Ma, et al.. (2023). A pharmacokinetic drug–drug interaction study between rosuvastatin and emvododstat, a potent anti‐SARS‐CoV‐2 (COVID‐19) DHODH (dihydroorotate dehydrogenase) inhibitor. Pharmacology Research & Perspectives. 11(2). e01076–e01076. 2 indexed citations
11.
Gao, Lan, et al.. (2023). Relative Oral Bioavailability and Food Effects of Two Sepiapterin Formulations in Healthy Participants. Clinical Pharmacology in Drug Development. 13(5). 506–516. 8 indexed citations
12.
Kong, Ronald, et al.. (2023). Quantitative Systems Toxicology Modeling Informed Safe Dose Selection of Emvododstat in Acute Myeloid Leukemia Patients. Clinical Pharmacology & Therapeutics. 115(3). 525–534. 5 indexed citations
13.
Ma, Jiyuan, Peter P. Giannousis, Martin Thoolen, et al.. (2023). Absorption, distribution, metabolism and excretion of 14 C-vatiquinone in rats, dogs, and human subjects. Xenobiotica. 53(5). 396–411. 5 indexed citations
14.
Laskin, Oscar L., Diksha Kaushik, Jiyuan Ma, et al.. (2023). A clinical pharmacokinetic drug-drug interaction study between dextromethorphan and emvododstat, a potent anti-SARS-CoV-2 dihydroorotate dehydrogenase inhibitor. European Journal of Clinical Pharmacology. 79(8). 1073–1080. 2 indexed citations
15.
16.
Branstrom, Arthur, Liangxian Cao, Bansri Furia, et al.. (2022). Emvododstat, a Potent Dihydroorotate Dehydrogenase Inhibitor, Is Effective in Preclinical Models of Acute Myeloid Leukemia. Frontiers in Oncology. 12. 832816–832816. 10 indexed citations
17.
Ma, Jiyuan, Nicole Risher, Valerie Northcutt, et al.. (2021). Ataluren metabolism: Ataluren-O-1β-acyl glucuronide is a stable circulating metabolite in mouse, rat, dog and human. Drug Metabolism and Pharmacokinetics. 38. 100393–100393. 1 indexed citations
18.
Shapiro, Geoffrey I., Edward O’Mara, Oscar L. Laskin, et al.. (2021). Pharmacokinetics and Safety of PTC596, a Novel Tubulin‐Binding Agent, in Subjects With Advanced Solid Tumors. Clinical Pharmacology in Drug Development. 10(8). 940–949. 14 indexed citations
19.
20.
Marsteller, Douglas, Christophe Gerald, Ronald Kong, et al.. (2008). The MCH1 receptor antagonist SNAP 94847 induces sensitivity to dopamine D2/D3 receptor agonists in rats and mice. European Journal of Pharmacology. 602(1). 66–72. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Dong Zhao Breakdown of academic impact, for papers by Liliana Torres-López Breakdown of academic impact, for papers by Laia Llovera Breakdown of academic impact, for papers by S Lenzen Breakdown of academic impact, for papers by Maurice Brollo Breakdown of academic impact, for papers by Lorraine Anderson Breakdown of academic impact, for papers by Manfred Thomas Breakdown of academic impact, for papers by Justyna M. Gawel Breakdown of academic impact, for papers by Yvonne Wohlfarter Breakdown of academic impact, for papers by Tetsushi Kataura
Rankless by CCL
2026